PURPOSE: To monitor the biodistribution of IgG1 aggregates upon subcutaneous (SC) and intravenous (IV) administration in mice and measure their propensity to stimulate an early immune response. METHODS: A human mAb (IgG1) was fluorescently labeled, aggregated by agitation stress and injected in SKH1 mice through SC and IV routes. The biodistribution of monomeric and aggregated formulations was monitored over 47 days by fluorescence imaging and the early immune response was measured by quantifying the level of relevant cytokines in serum using a Bio-plex assay. RESULTS: The aggregates remained at the SC injection site for a longer time than monomers but after entry into the systemic circulation disappeared faster than monomers. Upon IV administration, both monomers and aggregates spread rapidly throughout the circulation, and a strong accumulation in the liver was observed for both species. Subsequent removal from the circulation was faster for aggregates than monomers. No accumulation in lymph nodes was observed after SC or IV administration. Administration of monomers and aggregates induced similar cytokine levels, but SC injection resulted in higher cytokine levels than IV administration. CONCLUSION: These results show differences in biodistribution and residence time between IgG1 aggregates and monomers. The long residence time of aggregates at the SC injection site, in conjunction with elevated cytokine levels, may contribute to an enhanced immunogenicity risk of SC injected aggregates compared to that of monomers.
PURPOSE: To monitor the biodistribution of IgG1 aggregates upon subcutaneous (SC) and intravenous (IV) administration in mice and measure their propensity to stimulate an early immune response. METHODS: A human mAb (IgG1) was fluorescently labeled, aggregated by agitation stress and injected in SKH1 mice through SC and IV routes. The biodistribution of monomeric and aggregated formulations was monitored over 47 days by fluorescence imaging and the early immune response was measured by quantifying the level of relevant cytokines in serum using a Bio-plex assay. RESULTS: The aggregates remained at the SC injection site for a longer time than monomers but after entry into the systemic circulation disappeared faster than monomers. Upon IV administration, both monomers and aggregates spread rapidly throughout the circulation, and a strong accumulation in the liver was observed for both species. Subsequent removal from the circulation was faster for aggregates than monomers. No accumulation in lymph nodes was observed after SC or IV administration. Administration of monomers and aggregates induced similar cytokine levels, but SC injection resulted in higher cytokine levels than IV administration. CONCLUSION: These results show differences in biodistribution and residence time between IgG1 aggregates and monomers. The long residence time of aggregates at the SC injection site, in conjunction with elevated cytokine levels, may contribute to an enhanced immunogenicity risk of SC injected aggregates compared to that of monomers.
Authors: Binodh DeSilva; Wendell Smith; Russell Weiner; Marian Kelley; JoMarie Smolec; Ben Lee; Masood Khan; Richard Tacey; Howard Hill; Abbie Celniker Journal: Pharm Res Date: 2003-11 Impact factor: 4.200
Authors: Miranda M C van Beers; Melody Sauerborn; Francesca Gilli; Vera Brinks; Huub Schellekens; Wim Jiskoot Journal: Pharm Res Date: 2011-05-05 Impact factor: 4.200
Authors: Marisa K Joubert; Martha Hokom; Catherine Eakin; Lei Zhou; Meghana Deshpande; Matthew P Baker; Theresa J Goletz; Bruce A Kerwin; Naren Chirmule; Linda O Narhi; Vibha Jawa Journal: J Biol Chem Date: 2012-05-14 Impact factor: 5.157
Authors: Angelika J Freitag; Maliheh Shomali; Stylianos Michalakis; Martin Biel; Michael Siedler; Zehra Kaymakcalan; John F Carpenter; Theodore W Randolph; Gerhard Winter; Julia Engert Journal: Pharm Res Date: 2014-08-15 Impact factor: 4.200
Authors: Carly Fleagle Chisholm; Abby E Baker; Kaitlin R Soucie; Raul M Torres; John F Carpenter; Theodore W Randolph Journal: J Pharm Sci Date: 2016-03-25 Impact factor: 3.534
Authors: Wim Jiskoot; Grzegorz Kijanka; Theodore W Randolph; John F Carpenter; Atanas V Koulov; Hanns-Christian Mahler; Marisa K Joubert; Vibha Jawa; Linda O Narhi Journal: J Pharm Sci Date: 2016-04-01 Impact factor: 3.534
Authors: J Benjamin St Clair; Thiago Detanico; Katja Aviszus; Greg A Kirchenbaum; Merry Christie; John F Carpenter; Lawrence J Wysocki Journal: PLoS One Date: 2017-01-23 Impact factor: 3.240
Authors: Verena Rombach-Riegraf; Anette C Karle; Babette Wolf; Laetitia Sordé; Stephan Koepke; Sascha Gottlieb; Jennifer Krieg; Marie-Claude Djidja; Aida Baban; Sebastian Spindeldreher; Atanas V Koulov; Andrea Kiessling Journal: PLoS One Date: 2014-01-21 Impact factor: 3.240